[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Insel Gruppe AG, University Hospital Bern\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":693},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,152,0,25,[9,42,71,96,126,148,179,206,248,275,300,328,354,381,409,436,459,479,503,528,552,575,601,634,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100565914","maximal-medical-treatment-of-intracerebral-haemorrhage-pilot-trial---max-ich-pilot-trial-100565914",false,"NCT06648369","Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial","MAX-ICH","Inclusion Criteria:\n\n* Symptomatic imaging proven diagnosis of non-traumatic ICH\n* Vascular imaging (MR-\u002FCT-angiogram or DSA) on admission to rule out high suspicion of macrovascular bleeding source\n* Enrolment no later than 6 hours of symptom onset\n* Age \\>18 years, no upper age limit\n* Informed consent as documented by signature or fulfilling the criteria for emergency consent\u002F deferral consent\n\nExclusion Criteria:\n\n* Palliative care\u002Fcomfort therapy decision in the emergency department\n* ICH due to trauma (major head trauma \\\u003C24 hours of symptom onset causing loss of consciousness and thought to be sufficient to have caused the intracerebral bleeding)\n* High suspicion of ICH due to arteriovenous malformation (AVM), aneurysm or sinus-venous-thrombosis confirmed by neuroimaging, brain tumor, vasculitis, RCVS\u002FPRES or system disease (liver disease, inherit coagulopathy)\n* Severe ICH (haematoma volume \\>60ml or GCS \\\u003C8)\n* Haematoma evacuation or decompressive craniectomy within 72 hours planned or highly likely (isolated EVD is not an exclusion criterion)\n* Severe pre-morbid disability \\[modified Rankin scale (mRS) is ≥4\\]\n* Contraindication against the use of tranexamic acid\n* Active participation in another drug or devices trial concurrently\n* Female patient that are either pregnant or breastfeeding\n* Contraindications against Clevidipine (allergy to soja, lipid metabolism defect or known severe aortic stenosis)","ALL","18 Years","100 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The MAX-ICH pilot trial is a phase-II study aimed at assessing the feasibility and safety of a comprehensive care bundle for patients with intracerebral hemorrhage (ICH). This \"maximal medical treatment\" approach combines advanced interventions like intensive blood pressure control, rapid anticoagulation reversal, and tranexamic acid administration to potentially improve outcomes. The primary objective is to evaluate recruitment feasibility over 12 months, while secondary objectives include protocol adherence, safety monitoring, and the exploration of clinical outcomes. The study focuses on the critical first 72 hours of care to determine if this approach can be effectively implemented in clinical practice.",[28],"Intra Cerebral Hemorrhage","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2025-08-07",{"date":37,"type":22},"2028-11-30",{"name":39,"class":40},"Insel Gruppe AG, University Hospital Bern","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100641319","phase-4-calcitonin-gene-related-peptide-antibody-in-acute-mountain-sickness-100641319","NCT07653516","Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness","Calcitonin Gene-Related Peptide Antibody for Prevention of Acute Mountain Sickness: A Prospective Single-center, Randomized, Placebo-controlled, Double-blinded Study","Inclusion Criteria:\n\n* Age 18-60 years\n* No relevant previous illnesses in the preliminary examination\n* Written consent to participate in the study\n* Permanent residence \\\u003C1000 m\n* Men and women are included without prioritization\n* Negative urine pregnancy test if pregnancy cannot be ruled out with certainty\n\nExclusion Criteria:\n\n* Intolerance \u002F allergy to Fremanzeumab or other drug components\n* Acute or chronic lung disease\n* Blood pressure systolic ≥150 mmHg or diastolic ≥95 mmHg (average of two measurements) in subjects with or without blood pressure medication\n* Pre-existing cardiovascular diseases other than arterial hypertension (coronary heart disease, heart failure, pulmonary hypertension, atrial fibrillation, peripheral arterial occlusive disease)\n* Chronic headache, migraine\n* Diabetes mellitus\n* Smoking (\\>6 cigarettes\u002Fd) or equivalent nicotine substitution\n* Alcohol (\\>30 g\u002Fd) or other drug abuse\n* Overweight (BMI \\>30 kg\u002Fm2)\n* Other pre-existing conditions considered relevant by the investigators (liver disease, kidney disease, thyroid disease, Parkinson's disease, pheochromocytoma)\n* Stay \\>2000 m altitude within the last 8 weeks before the first study day\n* Medication taken within the last 2 months before the first study day, which could influence the data quality (e.g. corticosteroids) or the safety of the subjects (e.g. anticoagulation).\n* Blood donation within the last 2 months before the first study day\n* Pregnancy or breastfeeding\n* Participation in other clinical studies",true,"60 Years",{"count":52,"type":22},30,[54],"PHASE4","Acute mountain sickness (AMS) is a common condition that can occur when healthy people travel quickly to high altitude. Typical symptoms include headache, nausea, tiredness, dizziness, and poor sleep. In most cases, AMS improves with rest and by not climbing higher, but it can make mountaineering difficult and, in severe cases, can lead to dangerous complications.\n\nThe biological mechanisms that cause high-altitude headache and AMS are not yet fully understood. Some symptoms of AMS are similar to migraine, suggesting that both conditions may share common pathways in the nervous system. One possible pathway involves calcitonin gene-related peptide (CGRP), a substance known to play an important role in migraine.\n\nFremanezumab is an approved monoclonal antibody used to prevent migraine. It works by binding to CGRP and reducing its biological activity. This study will investigate whether a single dose of fremanezumab can also help prevent symptoms of AMS and high-altitude headache in healthy adults exposed to high altitude. To date, there are no clinical data on the effect of fremanezumab in AMS or high-altitude headache.\n\nThis is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 30 healthy adult volunteers will participate. Participants will be randomly assigned in a 1:1 ratio to receive either a single subcutaneous injection of fremanezumab 225 mg or placebo (saline). Neither the participants nor the investigators will know which treatment was given during the study. The study medication will be administered 1 week before ascent to Capanna Regina Margherita at 4554 meters above sea level. Participants will remain there for 46 hours under hypobaric hypoxic conditions.\n\nThe main goal is to determine whether fremanezumab reduces the severity of AMS compared with placebo. AMS symptoms will be measured using the Lake Louise Score, a standard questionnaire commonly used in altitude medicine. Additional assessments will include the incidence of AMS, headache characteristics, safety outcomes, vital signs, oxygen saturation, and the use of rescue medication. Symptoms will be assessed repeatedly during the high-altitude stay.\n\nOnly healthy adults aged 18 to 60 years living below 1000 meters will be eligible. People with important medical conditions, chronic headache or migraine, relevant cardiovascular or lung disease, pregnancy, or recent high-altitude exposure will be excluded. Participants will be closely monitored during the study. Rescue medication, oxygen, and descent to lower altitude will be available if needed.\n\nThis study may help improve understanding of how AMS develops and whether CGRP blockade could become a new preventive strategy for high-altitude headache and AMS. It may also improve understanding of links between altitude-related headache and migraine.",[57],"Acute Mountain Sickness",[59,60,61],"acute mountain sickness","calcitonin gene-related peptide antibody","migraine","NOT_YET_RECRUITING","2026-06-29",{"date":65,"type":33},"2026-07-01",{"date":67,"type":22},"2027-06-01",{"date":69,"type":22},"2027-07-31",{"name":39,"class":40},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100633992","fecal-microbiome-signature-of-multi-strain-probiotics-supplementation-in-children-and-adolescents-with-inflammatory-bowel-disease-100633992","NCT07533890","Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease","Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease - an Explanatory 1:1 Randomized Controlled Cross-Over Proof-of-Concept Trial With Blinded Outcome Assessment","MicroSig","Inclusion Criteria:\n\n* Signed informed consent\n* Diagnosis of inflammatory bowel disease according to actual guidelines (Porto Criteria)\n* General good health\n* Ability to understand and follow study procedures and understand informed consent\n* Age 5 -18 years\n* No probiotic therapy 4 weeks before entering into the study.\n\nExclusion Criteria:\n\n* Participation in other clinical studies interfering with study procedures.\n* Inability or contraindications to undergo the investigated intervention\n* Severe or acute flare of disease (for UC PUCAI score ≥35, for CD wPCDAI \\>40)\n* Treatment escalation within last 4 weeks for uncontrolled disease.\n* Antibiotic or probiotic therapy within the last 4 weeks.","5 Years",{"count":81,"type":22},40,[25],"In this study the intestinal microbiome and metabolic profiles of patients with inflammatory bowel disease will be determined upon probiotic intervention.",[85],"Inflamatory Bowel Disease",[87,88,89],"microbiome","inflammatory bowel disease","probiotics",{"date":30,"type":33},{"date":92,"type":33},"2026-05-01",{"date":94,"type":22},"2028-12",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":104,"minAge":4,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100629735","stockholm3-test-validation-in-men-on-active-surveillance-in-switzerland-chas3-trial-100629735","NCT07478536","Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)","Multicenter Validation of the Stockholm3 Test on Men on Active Surveillance: the CHAS3-Trial","CHAS3","Inclusion Criteria:\n\n* Adult Men ≥ 18 y. o.\n* Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)\n* First inclusion in Active Surveillance (AS) after 1st January 2022.\n* Scheduled for follow-up with systematic and\u002For Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available\n\nExclusion Criteria:\n\n* \\- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).\n\n  * Patient with intermediate- or high-risk prostate cancer\n  * Urinary catheterization within the past 6-8 weeks\n  * Contraindications to Magnetic Resonance Imaging (MRI) or biopsy","MALE",{"count":106,"type":22},350,"OBSERVATIONAL","The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.",[110,111],"Prostate Cancer","Active Surveillance for Prostate Cancer",[113,114,115,116,117,118],"Prostate","Cancer","Active Surveillance","Stockholm3","MRI","Biopsie","2026-06-18",{"date":121,"type":33},"2026-06-22",{"date":65,"type":22},{"date":124,"type":22},"2028-08-31",{"name":39,"class":40},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":147},"100577715","topanc-trial-survival-after-total-versus-partial-pancreaticoduodenectomy-for-adenocarcinoma-of-the-pancreatic-head-distal-cholangiocarcinoma-and-ampullary-cancer-100577715","NCT06801899","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer","ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer: a Multi-centric Randomized Controlled Trial","ToPanc","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years) scheduled to undergo PD for highly suspected or histologically proven, resectable pancreatic ductal adenocarcinoma (PDAC), distal cholangiocarcinoma (DCC), and\u002For ampullary cancer (pancreaticobiliary type)\n* Suspected pancreas anastomosis at high-risk for development of a postoperative pancreatic fistula (POPF) (grade \"D\" according to Schuh et al. (29): Estimation by CT scan, MRI, and\u002For Endoscopic Ultrasound\n* Written informed consent\n\nExclusion Criteria:\n\n* Duodenal carcinoma, ampullary cancer (intestinal type), neuroendocrine tumors, benign tumors, chronic pancreatitis\n* Medical conditions that do not allow appreciation of the nature, scope, and possible consequences of the trial as judged by the investigator\n* Pregnancy. A beta-Human Chorionic Gonadotropin (bHCG) pregnancy test must to be performed for women of child-bearing potential (defined as premenopausal women who have not undergone surgical sterilization)\n* Inability to follow the study procedures, e.g., due to psychological disorders, dementia, etc.",{"count":135,"type":22},170,[25],"The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage. The main question it aims to answer is:\n\nDoes total pancreas removal improve survival without reducing quality of life compared to partial removal?\n\nThe only study specific procedures are the collection of 2 blood samples (7.5ml for each time point, preoperatively and during the hospitalisation) and the completion of the questionnaires.",[139],"Pancreatic Cancer",{"date":141,"type":33},"2026-06-23",{"date":143,"type":33},"2026-06-01",{"date":145,"type":22},"2030-10",{"name":39,"class":40},10,{"id":149,"slug":150,"hasResults":12,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100641331","digitally-assisted-rehabilitation-at-home-for-older-adults-after-hip-surgery-grimsel-100641331","NCT07658664","Digitally Assisted Rehabilitation at Home for Older Adults After Hip Surgery (GRIMSEL)","Digitally Assisted Geriatric Home-rehabilitation in Older Patients After Hip Surgery (GRIMSEL): a Non-inferiority Randomized Controlled Trial","GRIMSEL","Inclusion Criteria:\n\n* Community-dwelling adults aged 55 to 80 years\n* Hospitalized for hip surgery with unrestricted weight bearing at University Hospital Bern\n\nExclusion Criteria:\n\n* Discharge to inpatient rehabilitation\n* inability to comply with a rehabilitation program (e.g. comorbidity that prevents 30min light workout, major cognitive impairment)\n* end-of life situation","55 Years","80 Years",{"count":159,"type":22},66,[25],"The goal of this clinical trial is to learn if a 12-week digitally supported, multimodal home rehabilitation program using the medical application Akina is as effective compared to routine care regarding functional independence in older adults undergoing hip surgery.\n\nHow is this multimodal home rehabilitation program received by patients? Is this multimodal home program at least as effective in terms of functional indpendence, muscle status, mobility and quality of life compared to routine care?\n\nResearchers will compare the multimodal rehabilitation program using the application Akina to routine care to see if the program works to treat patients after hip surgery.\n\nParticipants will:\n\nUndergo the rehab program at home or receive routine care (outpatient physiotherapy) for 12 weeks Visit the clinic after 6 and 12 weeks",[163,164,165,166],"Hip Surgery","Rehabilitation Program","Geriatrics Rehabilitation","Digital Health Intervention",[168,169,170,171],"functional independence","home-based rehabilitation","self-management","orthogeriatrics","2026-06-16",{"date":121,"type":33},{"date":175,"type":22},"2026-08",{"date":177,"type":22},"2028-08",{"name":39,"class":40},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100514299","early-closure-of-left-atrial-appendage-for-patients-with-atrial-fibrillation-and-ischemic-stroke-despite-anticoagulation-therapy-100514299","NCT05976685","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy","Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy","ELAPSE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization.\n* Recent (≤3 months) symptomatic ischemic stroke.\n* Active and ongoing anticoagulation therapy at stroke onset assessed based on medical history (i.e. any therapeutic oral anticoagulation therapy \\[Vitamin K antagonist\u002FDOAC according to prescription recommendations for AF; inadequate low-dose DOAC therapy allowed for inclusion\\] not stopped\u002Fpaused for \\>48 hours due to any reason, i.e. medical intervention or non-adherence).\n* Active or planned long-term therapy with DOAC\n\nExclusion Criteria:\n\n* Contraindications to DOAC therapy\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Stroke due to: Ipsilateral intra\u002Fextracranial high-grade stenosis, Isolated lacunar stroke, Other well-defined stroke aetiologies (i.e., endocarditis, vasculitis, Reversible Cerebral Vasoconstriction Syndrome \\[RCVS\\], Posterior Reversible Encephalopathy Syndrome \\[PRES\\], cerebral sinus venous thrombosis)\n* Previous persistent foramen ovale or atrial septum defect closure.\n* Rheumatic heart disease\n* Severe heart valve disease that requires treatment (severe aortic stenosis or regurgitation, severe mitral stenosis or regurgitation).\n* Contraindications for TEE (relevant esophageal varices, esophageal stricture, history of esophageal cancer).\n* Cardiac or non-cardiac surgical procedure within 30 days of randomization\n* Enrolled in another investigation of a cardiovascular device or investigating secondary prevention therapy.\n* Severely reduced Left Ventricular Ejection Fraction (LVEF) \\\u003C30%.\n* Severe renal impairment as described in the summary of medicinal product characteristics for the chosen DOAC (e.g. rivaroxaban, apixaban and edoxaban creatinine clearance \\\u003C15 ml\u002Fmin; dabigatran creatinine clearance \\\u003C30 ml\u002Fmin).\n* Hypertrophic cardiomyopathy\n* Intracardiac tumor\n* Ventricular thrombus\n* Acute cardiac decompensation\n* LAA is obliterated or surgically ligated\n* Persistent proximal LAA thrombus despite 4 weeks of anticoagulation (if a proximal thrombus in the LAA is found, anticoagulation with vitamin K antagonist (INR 2.5-3.5) may be started, and if the thrombus disappears, the patient may be eligible for LAAO)\n* Pregnancy or breastfeeding (pregnancy test in urine or blood to be performed at screening for women of childbearing potential)",{"count":188,"type":22},482,[25],"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%\u002Fyear. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is \"breakthrough\" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \\>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \\>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.",[192,193],"Ischemic Stroke","Atrial Fibrillation",[195,196,197],"Stroke","Direct oral anticoagulation","Left atrial appendage occlusion",{"date":199,"type":33},"2026-06-17",{"date":201,"type":33},"2024-05-01",{"date":203,"type":22},"2028-06-01",{"name":39,"class":40},29,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":229,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978","NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study",{"count":215,"type":22},160,[25],"Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[219,220,221,222,223,224,225,226,227,228],"Venous Thromboembolism (VTE)","Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Dyspnea","Functional Status","Pulmonary Embolism (Diagnosis)",[230,231,232,233,234,235,236,237,238],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","dyspnea","impact of early excercise-based rehabilitation","2026-06-11",{"date":241,"type":33},"2026-06-12",{"date":243,"type":33},"2025-12-17",{"date":245,"type":22},"2028-06",{"name":39,"class":40},6,{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100146616","swiss-diabetes-registry---swissdiab-study-100146616","NCT01179815","Swiss Diabetes Registry - SwissDiab Study","Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland","SwissDiab","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of diabetes mellitus according to ADA criteria\n* Informed consent\n\nExclusion Criteria:\n\n* Patients with gestational diabetes mellitus, patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions as well as patients with significantly reduced life expectancy (\\\u003C1 year) will be excluded",{"count":257,"type":22},1500,"Currently, the estimated number of people with diabetes mellitus is approximately 387 million people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of obesity the numbers of individuals with diabetes is increasing likewise. It has been shown that improving glycemic control is associated with a reduction in late complications of diabetes, such as cardiovascular and microvascular diseases. Therefore, treatment guidelines were established internationally by large and renowned associations and adopted by many countries.\n\nFor Switzerland only sparse data exist on the actual implementation of such recommendations and on patient's well-being. The Swiss Diabetes Registry - SwissDiab Study is a prospective cohort study aiming at including and collecting data of virtually all patients regularly seen and treated at the study centers (≈ 500 patients each), irrespective of type, duration of diabetes or treatment . This allows the evaluation of diabetes treatment strategies at these centers. Furthermore, risk indicators for micro- and macrovascular complications, mortality as well as costs and quality of life will be assessed. Data will be recorded through an internet-based, electronic database specifically designed for this study. At a later perspective it is planned to extend data collection to general practitioner\u002Ffamily doctor networks in order to include a larger and more representative sample of patients with diabetes in Switzerland.",[260],"Diabetes Mellitus",[262,263,264,265,266],"Patients with type 1 or type 2 diabetes mellitus","Monogenetic diabetes","Pancreatogenic diabetes,","Drug-induced diabetes, other forms","Cohort Studies","2026-06-08",{"date":239,"type":33},{"date":270,"type":4},"2010-01",{"date":272,"type":22},"2099-01",{"name":39,"class":40},4,{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":41},"100637995","mirna-quantification-in-patients-with-septic-shock-100637995","NCT07597122","MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK","MIRSEP","Inclusion Criteria:\n\nSeptic shock:\n\n* New onset (\\\u003C24h) of septic shock diagnosis according to Sepsis-3 definition\n* (suspected) infection\n* Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)\n* Serum lactate level \\> 2mmol\u002FL\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nCritically ill:\n\n* Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis\u002Fseptic shock according to Sepsis-3 definition\n* Minimum age of 18 years\n* Expected length of stay \\>48h\n* Written consent from an independent physician\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients known not to speak German or French\n* Patients with known.\n\n  1. Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or\n  2. current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose \\> 10 mg\u002Fday equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg\u002Fday is accepted.",{"count":284,"type":22},56,"Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.",[287],"Sepsis and Septic Shock",[289,290,291,292,293],"Septic shock","Sepsis induced immunusuppression","HLA-DR","miRNA","Monocytes",{"date":295,"type":33},"2026-06-02",{"date":143,"type":33},{"date":298,"type":22},"2027-12-31",{"name":39,"class":40},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":41},"100640405","litt-for-ultra-early-gbm-recurrence-100640405","NCT07616986","LITT for Ultra-early GBM Recurrence","Laser Interstitial Thermal Therapy for Ultra-Early, Pre-Radiotherapy Glioblastoma Recurrence","Inclusion Criteria:\n\n* Histologically confirmed glioblastoma, IDH-wildtype, regardless of MGMT status\n* ≥18 years of age\n* CRET\n* Karnofsky Performance Status (KPS) ≥70\n* No contra-indication for radio-chemotherapy\n* Scheduled for adjuvant radio-chemotherapy at University Hospital of Bern\n* Able to provide informed consent\n* No contra-indication for LITT\n* No pregnancy or active breast-feeding\n* No known coagulopathy independent of medication\n* No dissemination or multifocal disease\n* Patients lacking capacity to consent or considered vulnerable (e.g., minors, those under legal protection) are not included.\n\nExclusion Criteria:",{"count":308,"type":22},12,[25],"Glioblastoma (GBM) remains aggressive despite standard therapy (surgery (CRET) + RT\u002FCT). Over 40% of patients develop recurrence between surgery and pre-RT MRI, with median overall survival (OS) of 13.3m and 24.4m for patients with and without recurrence in pre-RT MRI, respectively. Reoperation is avoided as it delays adjuvant therapy.\n\nLITT offers a minimally invasive alternative that may:\n\n* Treat recurrence without delaying RT\u002FCT\n* Potentially sensitize tumors to subsequent therapy This study tests if LITT can be practically integrated within the critical 1-week window between pre-RT MRI and radiotherapy initiation, maintaining the adjuvant schedule.",[312,313],"Glioblastoma (GBM)","Glioblastoma - Category",[315,316,317,318,319,320],"LITT","Laser Interstitial Thermal Therapy","ultra-early recurrence","GMB","GMB recurrence","GMB ultra-early recurrence","2026-05-28",{"date":143,"type":33},{"date":324,"type":33},"2026-02-06",{"date":326,"type":22},"2028-01-31",{"name":39,"class":40},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100566327","phase-3-trial-to-assess-the-efficacy-of-empagliflozin-and-personalized-dietary-counseling-for-kidney-stone-prevention-100566327","NCT06653738","Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention","Randomized Placebo-controlled Trial to Assess Efficacies of EMPAgliflozin and Personalized Dietary Counselling for Kidney STONE Prevention in Patients With Calcium Kidney Stones Acronym: EMPASTONE Trial","EMPASTONE","Inclusion criteria:\n\n1. Written, informed consent.\n2. Age 18 years or older.\n3. Recurrent kidney stone disease with 2 or more stone episodes in the last 10 years prior to randomization.\n4. Last kidney stone containing 50% or more of CaOx, CaP or a mixture of both.\n5. If taking guideline-recommended medications for kidney stone prophylaxis (e.g. citrate salts), patients must have been on a stable regimen for at least 60 days before randomization and willing to remain on this stable regimen for the duration of the study.\n\nExclusion criteria:\n\n1. Known history of secondary or Mendelian causes of calcium nephrolithiasis\n2. Type I diabetes mellitus\n3. History of ketoacidosis\n4. Chronic Kidney Disease (CKD) stage 4 or 5 (defined as CKD-EPI eGFR \\\u003C30 mL\u002Fmin)\n5. Kidney transplant recipient\n6. History of recurrent urinary tract infections, defined as \\>3 episodes within the year prior to randomization\n7. Heart failure. Symptomatic patients with suspected heart failure must be evaluated before study enrollment\n8. Treatment with an SGLT2i within 4 weeks prior to randomization.\n9. Active cancer treatment\n10. Pregnancy and\u002For breastfeeding. Women of childbearing potential (i.e., premenopausal women who have not undergone surgical sterilization and are sexually active with a male partner) must have a negative urine or blood pregnancy test prior to enrollment\n11. Known allergy to the study drug\n12. Inability to understand and follow the study procedures\n13. Vulnerable individual, e.g. individual incapable of judgement or currently incarcerated or otherwise institutionalized (priosner), or refugee\n14. Concomitant participation in another interventional clinical trial within 4 weeks prior to randomization and during the current trial\n15. Prior enrollment in the EMPASTONE trial",{"count":337,"type":22},400,[339],"PHASE3","The aim of this randomized trial with a 2-by-2 factorial design is to test the efficacy of the SGLT2 inhibitor empagliflozin and personalized dietary counseling based on 24-hr urine collection results and dietary assessments for kidney stone recurrence prevention in patients with calcium kidney stones.\n\nStudy interventions:\n\n* Empagliflozin 10 mg once daily per os for 36 months\n* Personalized dietary counseling for 36 months.\n\nControl interventions:\n\n* Placebo once daily per os for 36 months\n* Generic dietary counseling for 36 months.",[342,343,344],"Kidney Stone","Nephrolithiasis","Dietary Exposure","2026-05-21",{"date":347,"type":33},"2026-05-27",{"date":349,"type":22},"2026-06",{"date":351,"type":22},"2030-09",{"name":39,"class":40},21,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":380},"100545791","acceptability-of-the-somnomat-casa-for-the-treatment-of-parkinsons-disease-100545791","NCT06386497","Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease","Overnight Treatment of Parkinson's Disease Using Vestibular Stimulation From a Rocking Bed (Somnomat Casa) - A Feasibility Study","Somnomat Casa","Inclusion Criteria:\n\n* Informed Consent signed by the subject\n* PD according to the MDS clinical diagnostic criteria for Parkinson's disease\n* Suffering from reduced sleep quality as defined by pathological cut-off (score of \\> 5) on the Pittsburgh Sleep Quality Index (PSQI)\n* Patients with stable antiparkinsonian, antidepressant, and sleep medications for six weeks before intervention and maintained on stable medication during the intervention period\n* Treatment without bilateral deep brain stimulation\n* Fluent in German\n\nExclusion Criteria:\n\n* Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).\n* Dementia as defined by a MOCA score lower than 24\u002F30\n* Weight \\> 150kg\n* Depression with acute suicidal ideation\n* Presence of major ongoing psychiatric illness such as acute non-controlled psychosis\n* Poor general health (e.g. non-controlled diabetes, uncontrolled arterial hypertension, therapy for malignancy)\n* Inability to follow the procedures of the study, e.g. filling out patient questionnaires due to language problems, psychological disorders, dementia, etc. of the participant\n* Participation in another interventional trial within the 30 days preceding and during the present study\n* Participants with PSQI score lower or equal 5","85 Years",{"count":364,"type":22},15,[25],"This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.",[368],"Parkinson Disease",[370,371,372,373],"Vestibular Stimulation","Sleep quality","Rocking bed","Feasibility",{"date":375,"type":33},"2026-05-22",{"date":377,"type":33},"2024-01-11",{"date":298,"type":22},{"name":39,"class":40},2,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":274},"100537211","phase-2-safety-of-biliary-intraductal-radiofrequency-ablation-in-patients-with-unresectable-extrahepatic-biliary-tract-cancer-100537211","NCT06274879","Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer (EBTC) Undergoing Systemic Anti-tumor Therapy: a Phase II, Multi-center, Randomized, and Controlled Study (Ablatio-bilica)","Ablatio","Inclusion criteria\n\n1. Male or female ≥18 years old.\n2. Histologically or cytologically confirmed diagnosis of previously untreated and unresectable\\*, locally advanced and\u002For metastatic extrahepatic biliary tract cholangiocarcinoma with obstructive jaundice (increased serum level of total bilirubin).\n3. ECOG performance status 0 to 2.\n4. Adequate bone marrow function: Neutrophil count ≥1.0 x 109\u002FL, platelet count ≥100 x 109\u002FL.\n5. Adequate renal function in case of cisplatin administration: Estimated Glomerular Filtration Rate (eGFR) ≥60mL\u002Fmin\u002F1.73m2.\n6. Willing and able to provide written informed consent.\n7. Planned initiation of any standard-of-care systemic anti-proliferative therapy against ETB.\n\n   \\*The reason for inoperability needs to be documented and categorized as follows:\n   * Wish of patient.\n   * Locally advanced or vascular invasion = surgically not removable.\n   * Remnant liver is not sufficient.\n   * Anatomic contraindications.\n   * Distant metastasis.\n   * Severe comorbidities.\n   * Other reasons. Exclusion criteria\n\n\u003C!-- -->\n\n1. Solely intrahepatic cholangiocarcinoma or mixed type liver tumors (cholangiocarcinoma with hepatocellular differentiation parts).\n2. Multiple hepatic metastases with significant blockage of one or more liver segments and\u002For less than 50% of liver parenchyma potentially drainable on pre-intervention imaging.\n3. In case of immune-checkpoint-inhibitor (ICI) administration, any autoimmune diseases including inflammatory disorders such as Crohn's disease, ulcerative colitis, Wegener granulomatosis, systemic lupus erythematosus, rheumatoid arthritis, Graves' disease.\n\n   Exceptions:\n\n   \\- Hypothyroidism following Hashimoto thyroiditis stable on hormone replacement.\n\n   \\- Patients with vitiligo.\n\n   \\- Any chronic skin disorders that do not require systemic treatment.\n4. Use of immunosuppressive medication within 3 weeks prior to ICI administration.\n\n   Exceptions:\n\n   \\- Topical or inhaled steroids.\n   * Systemic corticosteroids at physiologic doses not exceeding \\>10mg\u002Fd of prednisone or equivalent.\n5. Prior Self-Expandable Metal Stent (SEMS) placement in the biliary tree.\n6. Biliary obstruction of non-tumoral etiology.\n7. Platelets \\\u003C100 x 109\u002FL or International Normalized Ratio (INR) \\>1.5.\n8. Secondary tumor.\n\n   Exceptions:\n\n   \\- Tumor treated with curative intent without recurrence for more than 5 years.\n   * Non-melanoma skin cancer treated carcinoma in situ without evidence of disease.\n9. Pregnancy or lactation.\n10. Known or suspected non-compliance, drug, or alcohol abuse.\n11. Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the candidate.\n12. Participation in another interventional study within 30 days prior to enrollment.\n13. Previous participation in the current study.\n14. Other diseases like Human Immunodeficiency Virus, Liver cirrhosis Child-Pugh B or C, cardiac pacemaker, history of organ transplantation or condition likely to significantly decrease life expectancy i.e., life expectancy is less than 3 months according to investigator judgement.",{"count":390,"type":22},36,[392],"PHASE2","The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of systemic anti-tumor therapy with or without immune-checkpoint-inhibitor (ICI). The main question it aims to answer is whether it is safe to combine systemic anti-tumor therapy with or without ICI with and bRFA.\n\nParticipants will be assigned to either the control group or the experimental group. In the control group, the standard of care consists of endoscopy with stent placement in the bile duct and systemic anti-tumor therapy, whereas in the experimental group, bRFA will be performed in addition to the standard of care. Participants will be followed up for 6 months, during the follow-up, the stage of the tumor, blood examination, the duration of the stent from the insertion until its failure, adverse events and quality of life will be examined.\n\nResearchers will compare the standard of care alone to the experimental group to see if the additional bRFA procedure causes higher or no difference in adverse events rate.",[395],"Bile Duct Cancer",[397,398,399,400,401],"Durvalumab + chemotherapy","Radiofrequency ablation","Adverse events","Chemo-immune-checkpoint-inhibitor","Extra hepatic biliary tract cancer",{"date":403,"type":33},"2026-05-26",{"date":405,"type":33},"2026-05-20",{"date":407,"type":22},"2030-12-30",{"name":39,"class":40},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":49,"sex":17,"minAge":416,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":423,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":380},"100498042","speech-as-biomarker-for-emotion-movement-and-cognition-in-parkinsons-disease-100498042","NCT05765110","SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease","EMO-SPEECH-PD","Patients with Parkinson's Disease\n\nInclusion Criteria:\n\n* Written informed consent\n* Idiopathic PD according to the Movement Disorders Society Criteria;\n* Age of participants \\> 30 and ≤ 75 years;\n* Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus;\n* Fluent in German or French\n\nExclusion Criteria:\n\n* Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia);\n* Clinical diagnosis of aphasia;\n* Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.).\n* Cognitive impairment (Montreal Cognitive Assessment (MoCa) \\\u003C 24\u002F30 points);\n* Depression with acute suicidal ideation\n\nHealthy Controls\n\nInclusion Criteria:\n\n* Written informed consent\n* Adults from 50-70 years old;\n* Fluent in German or French\n\nExclusion Criteria:\n\n* Diagnosis of Parkinson's disease;\n* Cognitive impairment (Montreal Cognitive Assessment (MoCa) \\\u003C 24\u002F30 points);\n* Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.);\n* Clinical diagnosis of aphasia, dysarthria, and stuttering;\n* Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria","30 Years","75 Years",{"count":419,"type":22},80,[25],"With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.",[368],[424,425,426,427,428,429],"Speech","Emotion","Movement","Cognition","Biomarker","Automated speech analysis",{"date":375,"type":33},{"date":432,"type":33},"2023-01-03",{"date":434,"type":22},"2026-12-31",{"name":39,"class":40},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":444,"minAge":18,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":41},"100405527","prophylactic-laparoscopic-suspension-after-mccall-100405527","NCT04560543","Prophylactic Laparoscopic Suspension After McCall","Prophylactic Laparoscopic Suspension After McCall - Benefit and Longterm Outcome","LAPCALL","Inclusion criteria\n\n* LSC simple hysterectomy,\n* Neg. SS test if premenopausal\n* \\>18j,\n* Consent to participate in the study\n* Understanding of the German language\n\nExclusion criteria\n\n* Prolapse as indication for surgery\n* Known or suspected non-compliance\n* Additional incontinence procedures\n* Patients with deep infiltrating endometriosis\n* Irradiation pre- or postoperative\n* Pregnancy and lactation.\n* Conversion from laparoscopy to laparotomy\n* Inability to understand the study protocol","FEMALE",{"count":446,"type":22},114,[25],"There is prove of prolapse prevention in vaginal hysterectomy using the McCall suture. Poor and especially no long-term data exists for a standardized laparoscopic approach, but the few studies could show good anatomic results.\n\nThe aim is to test the effectiveness of the laparoscopic McCall suture compared to usual vaginal cuff closure in a randomized controlled double-blinded trial.",[450],"Prolapse Pelvic","2026-05-17",{"date":453,"type":33},"2026-05-19",{"date":455,"type":33},"2021-05-15",{"date":457,"type":22},"2032-12-31",{"name":39,"class":40},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":4},"100637391","phase-4-effect-of-dexmedetomidine-on-hemodynamic-stability-in-carotid-endarterectomy-reduced-norepinephrine-use-and-propofol-dosing-via-central-sympatholytic-action-100637391","NCT07597109","Effect of Dexmedetomidine on Hemodynamic Stability in Carotid Endarterectomy: Reduced Norepinephrine Use and Propofol Dosing Via Central Sympatholytic Action","Does the Co-administration of Dexmedetomidine Improve Hemodynamic Stability During Carotid Endarterectomy (CEA) Under General Anaesthesia? A Single-Centre Prospective Randomized Controlled Trial.","Inclusion Criteria:\n\n* age ≥18 years\n* ASA physical status 1-4\n* written informed consent provided.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years, Rapid sequence induction needed for surgery, higher grade atrioventricular block without pacemaker, severe hypovolaemia or bradycardia, uncontrolled hyper or hypotension, hypersensibility concerning the active substance Dexmedetomidine or any other component, serve liver disease, known malignant hyperthermia, cardiovascular instability or severe heart failure (EF ≤ 30% or \\> NYHA III), limited peripheral autonomic activity, pregnancy, rejection or lack of consent of the patient.",{"count":467,"type":22},44,[54],"1. Objective and Selection We refer to our research project as the \"research project\" in this information sheet. If you participate, you will be a participant.\n\n   In this research project, we aim to investigate the effect of the medication dexmedetomidine on blood pressure during surgery on your carotid artery. We are inviting you because all individuals undergoing carotid artery surgery may participate.\n2. General Information Due to your narrowing of the carotid artery, you require a planned procedure under general anesthesia. During this, your circulatory system and heart function will be continuously monitored through ongoing measurements to constantly track your condition. At the start of general anesthesia, heart rate, blood oxygen levels, and blood pressure will be monitored. Strong painkillers and anesthetic agents will then be administered for the general anesthesia. Additional medications will be given to maintain the anesthesia. Your condition will be closely and continuously monitored throughout the general anesthesia. At the end of the surgery, the anesthetic agents will be gradually reduced, allowing you to awaken from the anesthesia. In this context, we want to examine whether the additional administration of dexmedetomidine during carotid artery surgery reduces blood pressure fluctuations that may occur during such anesthesia.\n\n   The medication dexmedetomidine is approved for the Swiss market by Swissmedic and is commonly used today in many areas of anesthesia and intensive care medicine. It is even administered to pediatric patients in anesthesia. The goal of continuous dexmedetomidine administration during surgery is twofold: to reduce the need for other anesthetic agents while simultaneously minimizing blood pressure fluctuations that may arise during different surgical phases.\n\n   The scientific question is: Does additional administration of dexmedetomidine influence the intraoperative hemodynamic course and thus the clinical outcome after surgery? The study will be conducted over approximately 24 months at Inselspital Bern (single-center) with 44 patients. We are conducting this study in accordance with Swiss laws and all internationally recognized guidelines. The responsible cantonal ethics committee (KEK Bern, Murtenstrasse, Bern) has reviewed and approved the study. A description of this study is also available on the website of the Federal Office of Public Health: www.kofam.ch.\n3. Procedure The planned surgery will be performed independently of this study. Upon the patient's arrival in the operating room, they will be randomly assigned to one of two groups. One group will serve as the control group and receive standard general anesthesia according to our current hospital guidelines. The second group will receive the standard anesthesia plus the study medication dexmedetomidine in a precisely defined dose. Group allocation will be randomized and blinded (not disclosed to participants). The number of patients in both groups will be equal. Both groups will be treated and monitored in accordance with the recommendations and standards of the Department of Anesthesia and Pain Medicine at Inselspital Bern, as well as those of the Swiss Society for Anaesthesiology and Perioperative Medicine (SSAPM). Hemodynamic and cardiac function parameters will be closely monitored and recorded for all study participants. These data will be collected by the attending anesthesiologist.\n\nAt a precisely defined time point during the surgery (achievement of \"burst suppression\"), administration of the study medication will be stopped, and anesthesia will be adjusted according to surgical progress. After emergence from general anesthesia, you will be immediately assessed and then transferred to the recovery unit. During your stay on the recovery unit, circulatory parameters and your neurological status will be assessed at regular intervals.\n\nPrior to transfer to the regular ward the following day, a questionnaire regarding your neurological status will be completed, and all medications administered during your recovery unit stay will be recorded. The study will then be finished for all participating patients.",[471],"Steno-occlusive Disease","2026-05-12",{"date":453,"type":33},{"date":475,"type":22},"2026-09-01",{"date":477,"type":22},"2028-09-30",{"name":39,"class":40},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":485,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":487,"targetDuration":79,"studyType":107,"phases":4,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":41},"100636447","bern-intracoronary-optical-coherence-tomography-and-coronary-computed-tomography-angiography-registry-100636447","NCT07565805","Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry","Bern Intarcoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry","BIOCORE","Inclusion Criteria:\n\n1. ≥18 years of age\n2. Written informed consent\n3. CCTA within 3 months from invasive coronary angiography and OCT\n4. At least one vessel with ≥50% diameter stenosis on CCTA\n5. OCT performed in native coronary arteries (i.e. pre-PCI or no PCI)\n\nExclusion Criteria:\n\n1. CCTA performed more than 3 months from OCT\n2. Poor OCT quality\n3. Poor CCTA quality\n4. Coronary anomalies\n5. Prior PCI or CABG in the vessel imaged with OCT",{"count":488,"type":22},816,"Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry (BIOCORE) is a systematic institutional registry on patients undergoing paired CCTA and OCT for validation and development of advanced methods to determine coronary plaque morphology, lesion severity, PCI guidance, and it association with long-term clinical outcomes.",[491],"Coronary Artery Disease (CAD)",[493,494,495],"Coronary artery disease (CAD)","Optical coherence tomography (OCT)","Coronary computed tomography angiography (CCTA)","2026-05-07",{"date":472,"type":33},{"date":499,"type":33},"2025-10-17",{"date":501,"type":22},"2033-12-31",{"name":39,"class":40},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":380},"100581615","dietary-treatment-strategies-and-metabolic-control-in-glycogen-storage-disease-type-i-100581615","NCT06852612","Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I","Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I (GSD-DIET)","GSD-DIET","Inclusion Criteria:\n\n* Genetically and\u002For enzymatically confirmed diagnosis of GSDI (GSDIa or GSDIb)\n* Male or female ≥ 18y\n* Restriction of fructose intake in usual dietary treatment\n* Written informed consent\n\nExclusion Criteria:\n\n* Non-compliance with routine dietary treatment\n* Pregnancy or lactation\n* Liver transplant\n* Recurrent hospitalisations due to metabolic decompensation within the last 12 months\n* Severe chronic kidney disease with glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin\n* For GSDIb: Severe, uncontrolled symptomatic inflammatory bowel disease",{"count":512,"type":22},20,[25],"The present project will specifically assess metabolic effects of dietary interventions with controlled intake of fructose and fructose\u002Fgalactose in GSDI, with the aim to provide evidence whether relaxed dietary restrictions of fructose and galactose may be justified in treatment recommendations at least for adults, which would considerably enlarge food choice in everyday life of the patients with an expected positive impact on the quality of life of patients with this rare disorder.",[516],"Glycogen Storage Disease Type I",[518,519,520,521],"Gsd1","Metabolism","Fructose","Galactose",{"date":472,"type":33},{"date":524,"type":33},"2025-04-24",{"date":526,"type":22},"2027-03",{"name":39,"class":40},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":536,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":41},"100559069","coronary-artery-disease-assessment-strategies-in-tavi-patients-100559069","NCT06559332","Coronary Artery Disease Assessment Strategies in TAVI Patients","Randomized Trial of Coronary Artery Disease Assessment Strategies in Patients With Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation","CAT","Inclusion:\n\n• Severe aortic stenosis defined by aortic valve area (AVA) ≤1cm2 AND mean gradient ≥40 mmHg or peak velocity ≥4.0 m\u002Fs\n\nOR\n\nif mean gradient \\\u003C40 mmHg and peak velocity (Vmax) \\\u003C4 m\u002Fs and stroke volume indexed to body surface area (SVi) ≤ 35 mL\u002Fm2 and LVEF ≥50% then if CT-derived aortic valve calcium score \\>2000 Agatston units in men, \\>1200 in women\n\nOR\n\nif mean gradient \\\u003C40 mmHg and Vmax \\\u003C4 m\u002Fs and SVi ≤ 35 mL\u002Fm2 and LVEF \\\u003C50% then if CT-derived aortic valve calcification \\>2000 Agatston units in men, \\>1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (\\>20% increase in stroke volume) and AVA ≤1cm2\n\n* Coronary calcium score ≥ 400 Agatston units (derived from routine pre-TAVI CT) or known coronary artery disease\n* Selected for treatment with transfemoral TAVI.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Concomitant valvular heart disease or ascending aortic aneurysm with indication for surgery or intervention\n* Unprotected left main coronary stenosis \\>50% or left main not evaluable based on coronary computed tomography angiography derived from routine pre-TAVI CT\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%\n* New regional wall motion abnormalities on echocardiography\n* Myocardial infarction in previous 12 months\n* Coronary angiography in previous 12 months\n* Prior left main stenting","70 Years",{"count":538,"type":22},546,[25],"Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.\n\nAs the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit\u002Frisk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.\n\nThe CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).",[542,543,544],"Transcatheter Aortic Valve Replacement","Coronary Artery Disease","Heart Disease Risk Factors",{"date":546,"type":33},"2026-05-08",{"date":548,"type":33},"2025-03-11",{"date":550,"type":22},"2032-03-31",{"name":39,"class":40},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":364},"100512662","phase-4-monotherapy-with-p2y12-inhibitors-in-patients-with-atrial-fibrillation-undergoing-supraflex-stent-implantation-100512662","NCT05955365","Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing suprafleX Cruz Coronary Stent Implantation","MATRIX-2","Inclusion Criteria:\n\n* Age ≥18 years\n* Atrial fibrillation or flutter with an indication for oral anticoagulation using direct-acting oral anticoagulants (DOACs) for ≥12 months\n* Successful percutaneous coronary intervention in at least 1 lesion within the previous 7 days with no remaining lesions intended for treatment.\n* Free from major adverse events post qualifying PCI, including new onset chest pain suspected to be of ischemic origin, acute or subacute stent thrombosis, new-onset neurological signs or symptoms.\n* Written informed consent\n\nExclusion Criteria:\n\n* Planned staged percutaneous intervention procedure (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop indication to percutaneous valve intervention can undergo treatment more than 30 days after qualifying PCI.)\n* Cardioversion for treatment of atrial fibrillation within 1 month prior to inclusion or planned cardioversion\n* AF ablation procedure within 2 months prior to inclusion or planned AF ablation procedure\n* Prior mechanical valvular prosthesis implantation\n* Deep vein thrombosis\u002Fpulmonary embolism, at least moderately severe mitral stenosis or other clinical conditions than atrial fibrillation requiring long-term oral anticoagulation\n* Stroke within 1 month prior to randomization\n* Hemodynamic instability (persistent systolic blood pressure below 90 mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and\u002For use of percutaneous left ventricular assist devices)\n* Uncontrolled severe hypertension with a systolic blood pressure (BP) ≥180 mmHg and\u002For diastolic BP ≥120 mmHg\n* Severe renal impairment with estimated creatinine clearance (CrCL) \\\u003C15 mL\u002Fmin or on dialysis\n* Moderate or severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy\n* Any hypersensitivity or contraindications for direct oral anticoagulation or dual antiplatelet therapy with aspirin and a P2Y12 inhibitor\n* Any of the following abnormal local laboratory results prior to randomization: platelet count \\\u003C50 x109\u002FL or hemoglobin \\\u003C8 g\u002FdL\n* Known pregnancy or breast-feeding patients\n* Life expectancy \\\u003C1 year due to other severe non-cardiac disease\n* Planned surgery including coronary artery bypass grafting within the next 6 months",{"count":561,"type":22},3010,[54],"Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined.\n\nThe currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant.\n\nIn the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events.\n\nIn this study the investigators would like to investigate whether treatment with a single antithrombotic drug (\"monotherapy strategy\") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications (\"standard-of-care strategy\").",[565,566,567,568],"Percutaneous Coronary Intervention (PCI)","Atrial Fibrillation (AF)","Oral Anticoagulation","P2Y12 Inhibitor",{"date":546,"type":33},{"date":571,"type":33},"2023-12-18",{"date":573,"type":22},"2028-06-30",{"name":39,"class":40},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":536,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":590,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":596,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":41},"100493901","structured-shared-decision-making-for-patients-undergoing-savr-or-tavr-100493901","NCT05711186","Structured Shared Decision Making for Patients Undergoing SAVR or TAVR","Structured Shared Decision Making for Patients Undergoing Elective Surgical or Transcatheter Aortic Valve Replacement (TOGETHER): A Randomized-controlled Trial","TOGETHER","Inclusion Criteria:\n\n1. Age ≥ 70 years\n2. Symptomatic severe aortic stenosis defined by an aortic valve area ≤1.0 cm2 or an aortic valve area indexed to body surface area \\\u003C0.6cm2\u002Fm2\n3. Both SAVR and transfemoral TAVR as reasonable treatment options based on heart team decision\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 year irrespective of valvular heart disease\n2. Inability to provide informed consent\n3. Participation in another clinical trial with an active intervention",{"count":584,"type":22},140,[25],"Transcatheter aortic valve replacement (TAVR) is a well-established alternative to surgical aortic valve replacement (SAVR) for the treatment of patients with severe aortic stenosis regardless of surgical risk. While TAVR and SAVR share some of the benefits and risks, they importantly differ with regards to invasiveness, time to recovery, hemodynamics, as well as options for re-intervention and possibly valve durability. An early benefit of TAVR may be offset by late risks. Therefore, current guidelines of the European Society of Cardiology recommend an integration of patient values and preferences for the selection of the treatment modality.\n\nThe objective of the TOGETHER trial is to investigate the efficacy of a structured shared decision making approach (SDM) to improve patient-centered outcomes for the choice between SAVR and TAVR.\n\nTOGETHER is an investigator-initiated, randomized, open-label, single-center clinical trial. A total of 140 patients referred for treatment of symptomatic severe aortic stenosis and deemed to undergo TAVR or SAVR according to heart team decision will be randomized in a 1:1 ratio to structured SDM or usual care.",[588,589],"Aortic Valve Stenosis","Symptomatic Aortic Stenosis",[589,588,591,592,593,594,595],"SAVR (Surgical Aortic Valve Replacement)","Shared Decision-Making","TAVR (Transcatheter Aortic Valve Replacement)","TAVI (Transcatheter Aortic Valve Implantation)","Decision Support Techniques",{"date":546,"type":33},{"date":598,"type":33},"2023-04-17",{"date":298,"type":22},{"name":39,"class":40},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":609,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":620,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":41},"100605891","phase-4-landiolol-to-avoid-tachycardia-in-patients-at-risk-for-cardiovascular-events-undergoing-major-non-cardiac-surgery-100605891","NCT07168421","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery","LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery: a Feasibility Trial","LANTA-P","Inclusion Criteria:\n\n* Patients undergoing elective non-cardiac surgery defined as intermediate or high-risk by the 2022 european society of cardiology (ESC) guidelines\n* surgery performed under general anesthesia;\n* expected length of hospital stay ≥ 24 hours;\n* age ≥ 45 years;\n* at least two of the following risk factors:\n\n  * age ≥ 75 years\n  * arterial hypertension;\n  * ischemic heart disease (history of myocardial infarction or positive exercise test, current complaint of chest pain considered to be secondary to myocardial ischemia, use of nitrates, pathological Q waves, prior coronary revascularization);\n  * history of congestive heart failure;\n  * history of cerebrovascular disease;\n  * peripheral artery disease;\n  * diabetes mellitus;\n  * GFR ≤ 59 ml\u002Fmin pro 1.73 m2;\n  * pre-operative NTproBNP \\> 200 pg\u002Fml;\n* excessive sympathetic outflow as proven by exercise testing:\n\n  * impaired heart rate recovery (≤ 12 bpm within 1 minute after cessation of exercise); OR\n  * exaggerated heart rate response (≥ 12 bpm after 3 minutes of unloaded pedalling);\n\nExclusion Criteria:\n\n* unable to consent or follow study procedures;\n* absolute contraindications for exercise testing;\n* pregnancy or intention to become pregnant;\n* active cardiac conditions (such as unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease);\n* urgent \u002F emergency surgery;\n* already on β-blocker (within the last 30 days prior to recruitment);\n* contraindication for β-blocker therapy (bradycardia (HR \\\u003C 55 bpm), hypotension (systolic blood pressure \\\u003C 100 mmHg), severe peripheral vascular disease, severe asthma, allergy, higher-degree atrioventricular block);\n* severe preoperative anaemia (haemoglobin \\\u003C 100 g\u002FL) unless there is a plan set up and followed for correction prior to surgery;\n* planned intermediate care or intensive care admission;\n* prior enrolment in this trial.","45 Years",{"count":446,"type":22},[54],"Limiting perioperative tachycardia (aiming for a heart rate \\\u003C90 beats per minute throughout the perioperative period) using the ultra-short acting beta-blocker landiolol in patients with cardiovascular risk factors undergoing major surgery might lower the incidence of perioperative myocardial injury. Feasibility of the intervention needs to be proven prior to conduction of a larger trial.",[614,615,616,617,618,619],"Perioperative Myocardial Injury","Autonomic Dysfunction","Cardiovascular (CV) Risk","Major Surgery","Beta Blocker","Myocardial Injury After Non-cardiac Surgery",[621,622,623,624,625],"perioperative myocardial injury","major surgery","beta blocker","myocardial injury after non-cardiac surgery","autonomic dysfunction","2026-05-04",{"date":628,"type":33},"2026-05-05",{"date":630,"type":33},"2026-04-24",{"date":632,"type":22},"2028-03-01",{"name":39,"class":40},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":536,"enrollmentInfo":642,"targetDuration":4,"studyType":23,"phases":644,"briefSummary":645,"conditions":646,"keywords":650,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":380},"100498350","surgical-versus-non-surgical-treatment-of-thoracolumbar-burst-fracture-100498350","NCT05769114","Surgical Versus Non-Surgical Treatment of Thoracolumbar Burst Fracture","Outcome of Surgical Versus Primary Non-Surgical Treatment of Traumatic Thoracolumbar Spine Burst Fracture in Patients Without Neurological Symptoms: A Randomized Controlled Clinical Trial","A34RCT","Inclusion Criteria:\n\n* Age 18 - 70 years at inclusion\n* Acute traumatic burst fracture of the thoracolumbar spine (10th thoracic to 3rd lumbar vertebral body)\n* Informed consent for study participation\n\nExclusion Criteria:\n\n* Injury of the posterior tension band\u002Fposterior column of the thoracolumbar spine\n* Any neurological deficit (American Spinal Injury Association Impairment Scale \\[AISA\\] Grade A-D)\n* Pathological vertebral body fractures (diagnosed by MRI and CT scan), which, in the opinion of the research\u002Finvestigative team, would compromise (or interfere with) patients' ability to participate in the study\n* Concomitant spinal fractures at any other level of the spine outside the T10-L3 level, which, in the opinion of the research\u002Finvestigative team, would compromise (or interfere with) patients' ability to participate in the study\n* Multiple trauma or Injury Severity Score (ISS) \\> 16 or additional injuries according to the investigator may, which, in the opinion of the research\u002Finvestigative team, would compromise (or interfere with) patients' ability to participate in the study (impairment of early ambulation)\n* Any known previous spinal surgery in the thoracolumbar spine, which, in the opinion of the research\u002Finvestigative team, would compromise (or interfere with) patients' ability to participate in the study\n* Any severe, progressive, or uncontrolled medical or psychiatric condition, or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study\n* Known history of substance abuse (i.e., recreational drugs, alcohol) that would preclude reliable assessment in the opinion of the investigator\n* Pregnancy or women planning to conceive within the study period. All women included in this study must have a negative blood pregnancy test (human chorionic gonadotrophin (hCG) blood level at visit 1. If pregnancy occurs during the study period, the patients drop out of the study\n* Inability to follow the procedures of the study, e.g., due to inability to understand German, French or English, which, according to the investigator, may jeopardize the patient in case of participation in the study or prevents the patient from participating in the study",{"count":643,"type":22},52,[25],"Treatment for acute traumatic thoracolumbar burst fractures differs significantly across the world in patients without neurological impairments and without damage to the posterior column of the spine. This randomized controlled, non-inferiority clinical trial's goal is to evaluate the effectiveness of surgery versus initial non-surgical treatment for patients with traumatic thoracolumbar spine burst fractures who don't have any neurological symptoms.\n\nThe study's precise objectives are to:\n\n1. evaluate the clinical outcome (Oswestry Disability Index)\n2. evaluate the radiography result (restoration and maintenance of spinal alignment)\n3. determine the prevalence of complications\n\nat least 24 months of follow-up of neurologically unaffected patients with acute traumatic burst fractures. Both groups will get the same therapy using standardized methods: The surgical group's entire patient population will get combined anterior-posterior (360°) spinal fusion therapy. Three-point hyperextension orthoses will be used to treat all patients in the non-surgical group for six weeks following the injury.",[647,648,649],"SPINAL Fracture","Burst Fracture","Spinal Instability of Thoracolumbar Region",[651],"Traumatic Thoracolumbar Spine Burst Fracture",{"date":496,"type":33},{"date":654,"type":33},"2023-04-18",{"date":656,"type":22},"2030-03",{"name":39,"class":40},{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":666,"enrollmentInfo":667,"targetDuration":4,"studyType":23,"phases":669,"briefSummary":670,"conditions":671,"keywords":676,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":41},"100622038","questionnaire-on-congenital-cancer-signs-through-self-assessment-100622038","NCT07378423","Questionnaire on Congenital Cancer Signs Through Self-Assessment","Questionnaire on Congenital Cancer Signs Through Self-Assessment (QUOCCAS)","QUOCCAS","Inclusion Criteria:\n\n* The investigators will include newly diagnosed patients who received a cancer diagnosis included in the International Classification of Childhood Cancer version 3 (ICCC3) criteria, treated at participating hospitals\n\nExclusion Criteria:\n\n* Over 21 years of age","21 Years",{"count":668,"type":22},205,[25],"This clinical trial tests whether a patient- and caregiver-completed questionnaire (QUOCCAS) can accurately help identify children and adolescents with cancer who may have an underlying cancer predisposition syndrome (CPS). The study will also evaluate whether providing families with an educational brochure before their clinic visit improves their understanding of genetics and their satisfaction with care.\n\nThe main questions it aims to answer are:\n\n* Does QUOCCAS identify children at risk for CPS as accurately as physician-based tools and compared to genetic testing?\n* Does the Pre-Visit Preparation (PVP) brochure improve caregiver knowledge about genetics?\n* Does the PVP brochure improve caregiver satisfaction with the care and information they receive?\n\nParticipants will:\n\n* Complete the QUOCCAS questionnaire about family history, clinical features, and cancer signs\n* Provide a blood or saliva sample for genetic testing (whole-exome or whole-genome sequencing)\n* Randomly receive or not receive the educational Pre-Visit Preparation brochure before completing the questionnaire\n* Complete brief surveys on their knowledge and satisfaction",[672,673,674,675],"Cancer Predisposition Syndromes","Pediatric Cancer","Childhood Neoplasms","Hereditary Cancer Syndromes",[677,678,679,680,681,682,683,684,685],"Cancer Predisposition Syndrome (CPS)","Pediatric Oncology","Childhood Cancer","Genetic Testing","Whole-Exome Sequencing (WES)","Screening Tool","Patient-Reported Outcomes","Genetic Literacy","Whole-Genome Sequencing (WGS)","2026-04-30",{"date":92,"type":33},{"date":689,"type":33},"2026-04-01",{"date":691,"type":22},"2029-12-31",{"name":39,"class":40},""]